Melanoma



Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma


Condition:   Melanoma
Intervention:   Other: F-FDG PET/CT
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
Enrolling by invitation


A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: Pembrolizumab;   Drug: Nivolumab;   Drug: Indoximod;   Drug: Placebo
Sponsor:   NewLink Genetics Corporation
Recruiting


Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.


Condition:   Melanoma
Interventions:   Drug: Trametinib;   Drug: Dabrafenib;   Drug: INCB039110
Sponsors:   Massachusetts General Hospital;   Incyte Pharmaceuticals;   Sundry
Not yet recruiting


Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma


Condition:   Melanoma
Intervention:   Drug: PF-06688992
Sponsors:   Memorial Sloan Kettering Cancer Center;   Pfizer
Recruiting


Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma


Condition:   Metastatic Melanoma
Interventions:   Drug: Pembrolizumab;   Drug: Dabrafenib;   Drug: Trametinib
Sponsors:   Massachusetts General Hospital;   Merck Sharp & Dohme Corp.
Recruiting


Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era


Condition:   Mucosal Melanoma
Intervention:  
Sponsors:   Sun Yat-sen University;   First Affiliated Hospital, Sun Yat-Sen University;   Zhejiang Cancer Hospital
Recruiting


SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients


Conditions:   Melanoma;   Metastatic Melanoma
Interventions:   Radiation: SAbR;   Drug: Ipilimumab;   Drug: Nivolumab
Sponsor:   University of Texas Southwestern Medical Center
Not yet recruiting


LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma


Condition:   Melanoma
Interventions:   Drug: LY3022855;   Drug: Vemurafenib;   Drug: Cobimetinib
Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company
Recruiting


Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma


Condition:   Malignant Melanoma
Intervention:   Procedure: Wide Local Excision
Sponsor:   University of Kansas Medical Center
Recruiting


A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma


Condition:   Melanoma
Intervention:   Drug: PLX3397
Sponsors:   Daiichi Sankyo Co., Ltd.;   Daiichi Sankyo, Inc.
Active, not recruiting


BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: BGB324+pembrolizumab;   Drug: BGB324+dabrafenib and trametinib;   Drug: pembrolizumab;   Drug: dabrafenib and trametinib
Sponsors:   Haukeland University Hospital;   BerGenBio ASA
Recruiting


Nivolumab Plus Radiotherapy in Advanced Melanoma


Condition:   Melanoma
Interventions:   Biological: Nivolumab;   Radiation: hypofractionned radiotherapy
Sponsor:   Centre Hospitalier Universitaire de Nice
Recruiting


A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)


Condition:   Melanoma
Interventions:   Drug: pembrolizumab + epacadostat;   Drug: pembrolizumab + placebo
Sponsors:   Incyte Corporation;   Merck Sharp & Dohme Corp.
Active, not recruiting


Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: Standard therapy or clinical trial;   Drug: Matched targeted therapy;   Drug: Trametinib and / or supportive care
Sponsor:   Melanoma Institute Australia
Not yet recruiting


Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas


Condition:   Melanoma
Intervention:   Radiation: Protontherapy
Sponsor:   Centre Antoine Lacassagne
Active, not recruiting


Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy


Condition:   Melanoma
Intervention:   Drug: regorafenib
Sponsor:   Yonsei University
Recruiting


Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)


Condition:   Melanoma
Intervention:  
Sponsors:   Daniel Gareau;   Oregon Health and Science University;   University of California, Irvine
Recruiting


Melanoma Perception and Health Literacy in People of Color


Condition:   Melanoma
Interventions:   Behavioral: ABCDEs of Melanoma Skin Cancer;   Behavioral: ABCDEs of Melanoma
Sponsor:   Northwestern University
Completed


Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma


Condition:   Melanoma
Interventions:   Drug: All-Trans Retinoic Acid;   Drug: Ipilimumab
Sponsor:   University of Colorado, Denver
Active, not recruiting


LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma


Condition:   Melanoma
Interventions:   Drug: LGX818;   Drug: MEK162;   Drug: LEE011;   Drug: BGJ398;   Drug: BKM120;   Drug: INC280
Sponsor:   Array BioPharma
Active, not recruiting


Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery


Condition:   Recurrent Melanoma
Interventions:   Drug: selinexor;   Other: Correlative studies
Sponsors:   Kari Kendra;   Karyopharm Therapeutics Inc
Recruiting


Treatment of Advanced Melanoma With MK-3475 and Peginterferon


Condition:   Melanoma
Interventions:   Drug: MK-3475;   Drug: Peginterferon alfa-2b
Sponsors:   Hassane M. Zarour, MD;   Merck Sharp & Dohme Corp.;   Melanoma Research Alliance
Active, not recruiting


A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma


Condition:   Melanoma
Intervention:  
Sponsors:   Sanjiv Agarwala, MD;   Merck Sharp & Dohme Corp.
Recruiting


In Vivo Real-time Detection of Circulating Melanoma Cells


Condition:   Melanoma
Intervention:  
Sponsor:   University of Arkansas
Recruiting


Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma


Condition:   Melanoma
Interventions:   Drug: Talimogene laherparepvec;   Drug: Ipilimumab
Sponsor:   Amgen
Active, not recruiting

Refine Your Search Advanced Search